Inhibition of NKCC1 activity by bumetadine accelerates TMZ-treated glioblastoma cell apoptosis, and this suggests that NKCC1 activity remains functional and further regulates cell volume in TMZ-treated glioma, playing a role in [Cl−]i supplementation [24]. Here, SLC12A2 is linked to glioma.